Fellows Poster Review and Discussion

Fellows Poster Walks are led by expert faculty who will review and put into context the most significant and thought-provoking science at the meeting, while providing a venue for networking and informal discussion.

To register for a Fellows Poster Walk, select the Register button on the right-hand side in order to add a complimentary ticket to your registration. *

  Fellows Poster Review and Discussion: Prostate Cancer
Thursday, January 30 - 5:30 PM - 6:45 PM
Radiation Oncologist
Anthony D’Amico, MD, PhD
Dana-Farber Cancer Center

Abstract 2: Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).

Abstract 4: Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII).

Abstract 5: Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial.

Abstract 6: Independent validation of a genomic classifier in an at-risk population of men conservatively managed after radical prostatectomy.

Abstract 19: Factors associated with biopsy progression on active surveillance.

Abstract 8: Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study.

Abstract 10: Validation of a genomic classifier for predicting biochemical failure following postoperative radiation therapy in high-risk prostate cancer.

Abstract 13: Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.

Abstract 15: Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.

Abstract 17: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.

Abstract 22: The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.
Medical Oncologist
Mark Stein, MD
Rutgers Cancer Institute of New Jersey


  Fellows Poster Review and Discussion: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma

Friday, January 31 - 6:00 PM - 7:15 PM
Medical Oncologist
Joaquim Bellmunt, MD, PhD
Dana-Farber Cancer Institute

Radiation Oncologist
Fred Witjes, MD, PhD
Radboud University Nijmegen Medical Centre
Abstract9: 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study.

Abstract 13: Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.

Abstract 14: Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

Abstract 34: The performance of targeted magnetic resonance imaging/ultrasound fusion biopsy versus random 12-core biopsy for prediction of total prostate cancer tumor volume.

Abstract 35: Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.

Abstract 39: Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract 43: Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.

Abstract 50: Impact of obesity on outcomes after definitive dose escalated intensity modulated radiation therapy for localized prostate cancer.

Abstract 57: Using MRI/ultrasound fusion biopsy to detect clinically significant prostate cancer in the African American population.

Abstract 67: Using whole-genome sequencing to implicate the androgen receptor as the predominant driver of DNA breakpoints and fusion events in prostate cancer.

Abstract 70: A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.

Abstract 76: Metabolic response by choline positron emission tomography (cPET) to enzalutamide (ENZ) in castration-resistant prostate cancer (CRPC) patients (pts): Preliminary results of a monoinstitutional prospective study.

Abstract 100: Effect of adjuvant and salvage radiotherapy after radical prostatectomy on urinary continence.

Abstract 103: Positive margin length and Gleason grade of tumor focus at the margin predict for biochemical failure after radical prostatectomy in patients with pT2 prostate cancer.

Abstract 106: One-step ultrasound-based high dose rate (HDR) prostate brachytherapy with dose escalation to the dominant intra-prostatic lesion.

Abstract 115: A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

Abstract 117: Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.

Abstract 170: Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

*Poster Review and Discussion Sessions are limited to Fellows, Residents, and Junior Faculty only.